Short Interest in Atossa Therapeutics, Inc. (NASDAQ:ATOS) Expands By 5.8%

Atossa Therapeutics, Inc. (NASDAQ:ATOS) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 9,250,000 shares, an increase of 5.8% from the January 15th total of 8,740,000 shares. Based on an average daily volume of 876,500 shares, the short-interest ratio is presently 10.6 days.

Atossa Therapeutics Stock Up 1.9 %

NASDAQ:ATOS opened at $0.83 on Tuesday. Atossa Therapeutics has a one year low of $0.72 and a one year high of $2.31. The stock has a 50 day moving average price of $0.94 and a 200 day moving average price of $1.22.

Hedge Funds Weigh In On Atossa Therapeutics

Several large investors have recently modified their holdings of ATOS. SG Americas Securities LLC boosted its holdings in Atossa Therapeutics by 254.3% during the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after acquiring an additional 30,037 shares during the period. Intech Investment Management LLC acquired a new position in Atossa Therapeutics in the third quarter valued at approximately $29,000. The Manufacturers Life Insurance Company acquired a new position in shares of Atossa Therapeutics in the 3rd quarter valued at $75,000. State Street Corp grew its holdings in shares of Atossa Therapeutics by 4.2% during the third quarter. State Street Corp now owns 1,732,221 shares of the company’s stock worth $2,633,000 after purchasing an additional 69,180 shares during the last quarter. Finally, XTX Topco Ltd grew its stake in Atossa Therapeutics by 101.2% during the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock worth $75,000 after buying an additional 24,951 shares during the last quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on ATOS shares. Ascendiant Capital Markets upped their price objective on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. StockNews.com cut shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Atossa Therapeutics in a research report on Thursday, January 30th.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.